DEA Emergency and Temporary Scheduling: Authority, Notice, and Duration

DEA emergency scheduling is the process, set out in 21 U.S.C. § 811(h), that lets the Drug Enforcement Administration place an unscheduled substance into Schedule I on a temporary basis when it finds the drug poses an imminent hazard to public safety. The order takes effect after a 30-day notice period, lasts two years with a possible one-year extension, and carries the full criminal penalties of any other Schedule I substance from the day it is published.¹

The Authority and What It Reaches

The Controlled Substances Act sorts regulated drugs into five schedules based on abuse potential, accepted medical use, and safety.² Adding a new substance permanently under 21 U.S.C. § 811(a) requires detailed scientific findings, coordination with the Department of Health and Human Services, and formal notice-and-comment rulemaking. That work can take years.

Section 811(h) is the shortcut. It gives the Attorney General authority to place a substance temporarily in Schedule I when that step is “necessary to avoid an imminent hazard to the public safety.” In practice, the Attorney General has delegated the power to the DEA Administrator, who signs the orders.¹

The authority has hard limits. The substance cannot already appear on any of the five schedules. It also cannot have an approved new drug application or an active investigational exemption under the Federal Food, Drug, and Cosmetic Act. If a drug is already listed on Schedule IV, the DEA cannot use § 811(h) to move it to Schedule I; that requires standard rulemaking.¹

What the DEA Has to Show

Permanent scheduling weighs eight statutory factors. Temporary scheduling weighs only three of them, drawn from 21 U.S.C. § 811(c).¹

Factor 4, the history and current pattern of abuse: how the substance is being used, how people take it, and whether users are shifting to it from other drugs.
Factor 5, the scope, duration, and significance of abuse: hospitalizations, overdose deaths, poison-center calls, and law enforcement seizures.
Factor 6, the risk to public health: what danger the compound poses to the population, with fatal respiratory depression or unpredictable psychotic effects weighing heavily.

The statute also directs the agency to consider actual abuse, diversion from legitimate channels, and clandestine importation, manufacture, or distribution. The record supporting an imminent-hazard finding is typically built from toxicology reports, medical examiner data, emergency room records, and forensic lab analyses of seized samples.

The 30-Day Notice Period

Emergency scheduling is faster than standard rulemaking but not instant. Two things have to happen at least 30 days before the order can take effect.¹

First, the DEA publishes a notice of intent in the Federal Register identifying the substance, explaining why it poses an imminent hazard, and summarizing the supporting evidence.³ Second, the DEA transmits notice of the proposed order to the Secretary of Health and Human Services. The 30-day clock runs from whichever of those events happens later.

HHS’s role at this stage is consultative. In permanent scheduling, HHS scientific findings carry significant weight and must be requested before the DEA acts. Temporary scheduling explicitly sidesteps that requirement: the statute lets the Attorney General act “without regard to the requirements of subsection (b) relating to the Secretary of Health and Human Services.” The DEA must take any HHS comments submitted during the 30-day window “into consideration,” but HHS cannot block the order.¹

After the 30 days pass, the DEA publishes a final order in the Federal Register and the substance becomes controlled as of the effective date named in that order.

How Long a Temporary Order Lasts

A temporary order stays in effect for two years from its issuance date. If the DEA has already started permanent scheduling proceedings under § 811(a)(1) during that window, the agency can extend the temporary order for up to one additional year, for a maximum of three years total.¹

If permanent scheduling concludes before the temporary order runs out, the temporary order is vacated and replaced by whatever permanent classification the rulemaking produces. If the DEA does not act within the two-year (or extended three-year) window, the temporary order lapses and the substance returns to uncontrolled status. That sunset is one of the few structural checks on the emergency power. Congress has sometimes overridden it by statute for specific substance classes, but those legislative extensions are a separate mechanism from the DEA’s own one-year extension.

Criminal Penalties from Day One

Once the final order takes effect, distributing or manufacturing the newly scheduled substance carries the same penalties as trafficking any other Schedule I drug. Under 21 U.S.C. § 841(b), a first conviction for distributing a Schedule I controlled substance can bring up to 20 years in prison and fines up to $1 million. Larger quantities that trigger the enhanced tiers can push fines to $10 million for an individual and $50 million for an organization.⁴

These penalties attach the moment the final order publishes. There is no grace period for distributors to wind down.

No Court Challenge to the Scheduling Order

Temporary orders are shielded from judicial review. The statute states directly that an order issued under § 811(h)(1) “is not subject to judicial review.”⁵ A defendant charged with distributing a temporarily scheduled substance cannot argue in court that the DEA’s imminent-hazard finding was wrong, that the evidence was thin, or that the substance should not have been placed in Schedule I.

Other elements of a prosecution remain open to challenge: whether the defendant actually possessed the substance, whether the search was lawful, whether the required mental state was present. The scheduling decision itself is treated as settled. That is a sharp break from permanent scheduling, where affected parties can petition the federal courts of appeals for review.

What Happens for Researchers, Manufacturers, and Distributors

A temporary order also triggers immediate regulatory obligations for anyone who handles the substance professionally. On the effective date, the substance becomes subject to all Schedule I controls: storage, record-keeping, and reporting.

Anyone not already registered with the DEA to handle the substance must stop handling it on the effective date unless an approved registration is already in place. There is no grace period for new applicants. A narrow carve-out exists for researchers who already hold a DEA registration to work with a different Schedule I substance. They may continue research on the newly scheduled compound if they submit an application for registration, or a modification of their existing registration, within 90 calendar days of the effective date.³

A Schedule I research registration is more demanding than a lower-schedule registration. The application must include a detailed protocol covering the researcher’s qualifications, the purpose and design of the research, the specific substances and quantities, secure storage arrangements, and whether human subjects are involved. Clinical investigations require a Notice of Claimed Investigational Exemption for a New Drug (IND) with the FDA in place of the DEA protocol.⁶ These steps can freeze ongoing research for months.

Related Tools That Are Not the Same Thing

Two other mechanisms often come up alongside emergency scheduling and are worth separating out.

The Federal Analogue Act, at 21 U.S.C. § 813, treats a “controlled substance analogue” as a Schedule I substance for purposes of federal criminal law when it is intended for human consumption.⁷ A substance qualifies if it is chemically similar to a Schedule I or II drug and produces similar stimulant, depressant, or hallucinogenic effects on the central nervous system, or if the distributor intends or represents it to have those effects.⁸ Analogue prosecutions are harder to win because the government must prove the analogue definition is met at trial, often through expert testimony, and the Supreme Court held in McFadden v. United States that the government must also prove the defendant knew they were dealing with a controlled substance.⁹ That evidentiary burden is one reason the DEA often pursues temporary scheduling even when the Analogue Act could theoretically apply.

Section 811(d) provides a separate temporary-scheduling power for treaty compliance. When the United States commits under a treaty like the Convention on Psychotropic Substances to control a substance, and standard proceedings will not conclude within the required timeframe, the Attorney General can issue a temporary order placing the substance in Schedule IV or V.¹ The domestic findings on abuse potential, medical use, and safety are not required; the sole justification is treaty compliance. Penalties and controls track the lower schedule assigned, not Schedule I.

1
Office of the Law Revision Counsel. 21 USC 811 – Authority and Criteria for Classification of Substances
2
Office of the Law Revision Counsel. 21 USC 812 – Schedules of Controlled Substances
3
Federal Register. Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
4
Office of the Law Revision Counsel. 21 USC 841 – Prohibited Acts A
5
Office of the Law Revision Counsel. 21 US Code 811 – Authority and Criteria for Classification of Substances
6
eCFR. 21 CFR 1301.18
7
Office of the Law Revision Counsel. 21 USC 813 – Treatment of Controlled Substance Analogues
8
Office of the Law Revision Counsel. 21 US Code 802 – Definitions
9
Justia. McFadden v. United States